2023
Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosis
2022
Treating Hepatitis C in Individuals With Previous Incarceration: The Veterans Health Administration, 2012–2019
Hawks L, Wang E, Butt A, Crystal S, Keith McInnes D, Re V, Cartwright E, Puglisi L, Haque L, Lim J, Justice A, McGinnis K. Treating Hepatitis C in Individuals With Previous Incarceration: The Veterans Health Administration, 2012–2019. American Journal Of Public Health 2022, 113: 162-165. PMID: 36480765, PMCID: PMC9850617, DOI: 10.2105/ajph.2022.307152.Peer-Reviewed Original Research
2019
Author response to Letter to the Editor: ‘Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient’
Ortiz GA, Sayyar M, Garcia‐Tsao G. Author response to Letter to the Editor: ‘Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient’. Liver International 2019, 40: 990-991. PMID: 31749290, DOI: 10.1111/liv.14302.Commentaries, Editorials and LettersConceptsHepatic venous pressure gradientSustained virologic responseVenous pressure gradientVirologic responsePlatelet countOutcomes of Direct-Acting Antiviral Treatment of Psychiatric Patients with Comorbid Hepatitis C Virus Infection
Gayam V, Jegede O, Tiongson B, Mandal AK, Sidhu J, Garlapati P. Outcomes of Direct-Acting Antiviral Treatment of Psychiatric Patients with Comorbid Hepatitis C Virus Infection. Digestive Diseases 2019, 38: 232-239. PMID: 31494648, DOI: 10.1159/000502514.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionC virus infectionNon-psychiatric patientsPsychiatric patientsPsychiatric diagnosisAntiviral treatmentVirus infectionTreatment responsePsychiatric disordersComorbid hepatitis C virus (HCV) infectionDirect-acting antiviral treatmentRetrospective cohort observational studyComorbid substance use disorderNeuropsychiatric adverse effectsPrior treatment statusSustained virologic responseCohort observational studyPrimary psychiatric diagnosisComorbid substance abusePrimary care practicesSubstance use disordersHCV patientsVirologic responseHigh burdenObservational studyIncreased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores
Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019, 157: 1264-1278.e4. PMID: 31356807, PMCID: PMC6815714, DOI: 10.1053/j.gastro.2019.07.033.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCarcinoma, HepatocellularFemaleHepatitis CHumansIncidenceLiver CirrhosisLiver NeoplasmsMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsVeterans Health ServicesConceptsFIB-4 scoreSustained virologic responseAnnual HCC riskHCC riskHCV eradicationAnnual incidenceLower riskHepatitis C virus eradicationHigh FIB-4 scoreAbsolute annual riskHCV antiviral treatmentFibrosis-4 scoreInterferon-treated patientsVeterans Health AdministrationHepatocellular carcinoma riskHigh enough riskBaseline cirrhosisIncident HCCVirologic responseFIB-4HCC surveillanceHCV infectionAntiviral treatmentCarcinoma riskCirrhosisThe accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal Of Viral Hepatitis 2019, 26: 329-336. PMID: 30412325, DOI: 10.1111/jvh.13037.Peer-Reviewed Original ResearchMeSH KeywordsAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesData Interpretation, StatisticalFemaleGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMalePredictive Value of TestsQuinoxalinesReproducibility of ResultsSensitivity and SpecificitySulfonamidesSustained Virologic ResponseViral LoadConceptsBaseline viral loadResistance-associated substitutionsNS5A resistance-associated substitutionsEBR/GZRElbasvir/grazoprevirGenotype 1a infectionViral loadNegative predictive valuePositive predictive valuePredictive valueBaseline NS5a resistance-associated substitutionsHepatitis C virus infectionPoor negative predictive valueEuropean treatment guidelinesC virus infectionSustained virologic responseHigh positive predictive valueEBR 50GT1a infectionVirologic failureVirologic responseTreatment guidelinesTreatment outcomesVirus infectionStratification factors
2017
Infectious Disease-Led Hepatitis C Care in a Primary Care Clinic Setting: Cascade of Care Modeling and Experiences From an Integrated Clinic
Adamson P, Canterino J. Infectious Disease-Led Hepatitis C Care in a Primary Care Clinic Setting: Cascade of Care Modeling and Experiences From an Integrated Clinic. Open Forum Infectious Diseases 2017, 4: s200-s200. PMCID: PMC5632141, DOI: 10.1093/ofid/ofx163.386.Peer-Reviewed Original ResearchPrimary care clinicsChronic HCV infectionSustained virologic responseChronic HCVCare modelCare clinicsHCV clinicStudy periodHCV infectionClinic appointmentsHepatitis C virus infectionHepatitis C virus (HCV) treatmentPrimary care clinic settingCascade of careChronic HCV prevalenceC virus infectionHCV viral loadHepatitis C careInfectious disease physiciansC virus treatmentPrimary care settingHCV prevalenceVirologic responseHCV treatmentChart reviewSafety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study. Hepatology 2017, 66: 1090-1101. PMID: 28504842, PMCID: PMC5756478, DOI: 10.1002/hep.29258.Peer-Reviewed Original ResearchConceptsSustained virologic responseOmbitasvir/paritaprevir/ritonavirParitaprevir/ritonavirTransplant recipientsLiver transplantKidney transplantAntiviral therapyLarge prospective observational cohort studyChronic hepatitis C virusLiver-kidney transplant recipientsProspective observational cohort studySolid organ transplant recipientsHepatitis C virus (HCV) treatmentBaseline total bilirubinHCV-TARGET studyPrior antiviral therapyAbsence of cirrhosisKidney transplant recipientsLiver transplant recipientsObservational cohort studyOrgan transplant recipientsC virus treatmentGlomerular filtration rateCessation of treatmentSOF/ledipasvirEffect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD
Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, Brancale J, Xu D, Wisocky J, Lin MV, Kim AY, Thadhani R, Chung RT. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. Clinical Journal Of The American Society Of Nephrology 2017, 12: 1615-1623. PMID: 28882857, PMCID: PMC5628711, DOI: 10.2215/cjn.02510317.Peer-Reviewed Original ResearchConceptsSustained virologic responseAdverse eventsVirologic responseAntiviral therapyOverall sustained virologic responsePrior solid organ transplantHepatitis C virus (HCV) therapyEffect of sofosbuvirEfficacy of sofosbuvirHepatitis C cureRetrospective observational cohortC virus infectionSerious adverse eventsSolid organ transplantsC virus therapyCohort of patientsLarge health care systemPost-treatment followHepatitis C virusHealth care systemBaseline eGFRTreatment discontinuationObservational cohortKidney functionRegression modelsImplementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. PMID: 28237054, DOI: 10.1016/j.jsat.2016.12.014.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOpioid treatment programsPercent of patientsHCV treatmentHCV infectionActing antiviralsTreatment outcomesTreatment programOral HCV treatmentSustained virologic responseHCV treatment outcomesRoutine clinical careOngoing drug useVirologic responseRetrospective studyClinical careGeneral populationPatientsDrug useTreatmentOutcomesAntiviralsInfectionPercentPWID
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevirComparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C
Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, Colby CL, Canterbury K, Warner J, Therneau TM. Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. Mayo Clinic Proceedings 2014, 89: 595-601. PMID: 24661475, PMCID: PMC4160303, DOI: 10.1016/j.mayocp.2014.01.024.Peer-Reviewed Original ResearchConceptsRapid virologic responseChronic hepatitis CVirologic responseEarly virologic responseTriple therapyDual therapyHepatitis CP-IFNSustained virologic responseTreatment response categoriesTreatment-naive patientsPhase 3 trialRBV dose reductionPrior nonresponsePrior relapseCirrhosis statusProspective databaseViral hepatitisHemoglobin levelsAntiviral therapyWeek 4Dose reductionMean decreaseEligibility criteriaPatients
2012
Management of chronic hepatitis C infection in children
Porto AF, Tormey L, Lim JK. Management of chronic hepatitis C infection in children. Current Opinion In Pediatrics 2012, 24: 113-120. PMID: 22157364, DOI: 10.1097/mop.0b013e32834eb73f.Peer-Reviewed Original ResearchConceptsChronic hepatitis C infectionHepatitis C infectionC infectionPeginterferon αAntiviral therapyLiver fibrosisGenotype 1Global public health burdenDevelopment of cirrhosisSustained virologic responseIndolent clinical courseLarge prospective studiesProgressive liver fibrosisPublic health burdenImportant clinical implicationsMajority of childrenAreas of controversyVirologic responseViral eradicationCombination regimensInfected childrenClinical courseProspective studyTreatment courseEarly treatmentDeveloping a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication
Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication. The American Journal Of Drug And Alcohol Abuse 2012, 38: 206-212. PMID: 22242700, PMCID: PMC5573865, DOI: 10.3109/00952990.2011.643975.Peer-Reviewed Original ResearchConceptsSustained virologic responseEarly virologic responseMethadone maintenance treatmentHepatitis C treatmentSelf-administered therapyHepatitis C virusHCV treatmentVirologic responseAdherence supportWeek 12HCV treatment adherenceOpioid-dependent patientsBlood-borne infectionsMethadone-maintained patientsCompletion of treatmentCase-control studyMethadone maintenance clinicsMethadone maintenance programMental illness comorbidityConcurrent substance useC treatmentObserved therapyHCV genotypesHIV statusIllness comorbidity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply